Portuguese Biovance Capital led an 11 million euro Series A round in Seville biotech Vaxdyn, investing four million euros in this funding. This round also featured participation from the European Innovation Council (EIC) fund and the Impacto Andalucía Innovación y Desarrollo fund managed by Arcano Partners. Biovance Capital had already invested 300 thousand euros in the company in 2021.
Vaxdyn is developing vaccines against highly pathogenic and antibiotic-resistant bacteria, including the species Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa and Escherichia coli. This investment will allow the company to advance to clinical evaluation of the K-VAX vaccine through a Phase 1 clinical trial aimed at preventing infections caused by Klebsiella pneumoniae and Acinetobacter baumannii.
Ricardo Perdigão Henriques, managing partner at Biovance Capital, stated that he was very pleased to support Vaxdyn in the development of K-VAX toward the clinic, considering this a potential new vaccine that could save lives worldwide. André Albergaria, principal at Biovance Capital, highlighted that antimicrobial resistance is one of the most pressing global health challenges of our time, and that K-VAX has the potential to protect against potentially fatal bacteria associated with severe antibiotic-resistant pneumonia, urinary tract infections and bloodstream infections.
The 11 million euro round will also be complemented by grants from the EIC Accelerator and CARB-X, an international organization with 800 million dollars dedicated to supporting the development of technologically advanced antibacterials. This is the third investment from the Biovance Capital Fund I and the second investment the fund has made in Southern Europe, reflecting its commitment to the region given the high potential of its biotechnology sector.




